Pulmonary alveolar regeneration in adult COVID-19 patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.05.10.20097634: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Human specimens: All experiments with human tissue samples were performed under protocols approved by the Institutional Review Boards at National Institute of Biological Sciences, Beijing and Wuxi People’s Hospital. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The COVID-19 lung tissues were collected from lung explants of the COVID-19 patient (male, age 58yr). Table 2: Resources
Antibodies Sentences Resources The primary antibodies used were as follows: rabbit anti-Collagen I (1:300), mouse anti-a-SMA (1:300), rabbit anti-Prospc (1:500), mouse anti-HTII-280 (1:50), mouse anti-HTI-56(1:50), rat anti-KI67 … SciScore for 10.1101/2020.05.10.20097634: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Human specimens: All experiments with human tissue samples were performed under protocols approved by the Institutional Review Boards at National Institute of Biological Sciences, Beijing and Wuxi People’s Hospital. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The COVID-19 lung tissues were collected from lung explants of the COVID-19 patient (male, age 58yr). Table 2: Resources
Antibodies Sentences Resources The primary antibodies used were as follows: rabbit anti-Collagen I (1:300), mouse anti-a-SMA (1:300), rabbit anti-Prospc (1:500), mouse anti-HTII-280 (1:50), mouse anti-HTI-56(1:50), rat anti-KI67 (1:200), rabbit anti-CLDN4 (1:500), rabbit anti-SFN (1:500), rat anti-KRT8 (1:200). anti-Collagen Isuggested: (Novus Cat# NB300-289, RRID:AB_2082167)anti-a-SMAsuggested: (Boster Biological Technology Cat# BM0002, RRID:AB_2811044)anti-Prospcsuggested: Noneanti-HTII-280suggested: Noneanti-HTI-56suggested: Noneanti-KI67suggested: (Novus Cat# NBP1-79013-200ul, RRID:AB_11005815)anti-CLDN4suggested: (LSBio (LifeSpan Cat# LS-C79394-500, RRID:AB_1592275)anti-SFNsuggested: (LSBio (LifeSpan Cat# LS-C34771-500, RRID:AB_970111)anti-KRT8suggested: (LSBio (LifeSpan Cat# LS-C11223-200, RRID:AB_741890)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
